Mair Therapeutics Awarded Health~Holland Grant.
NIJMEGEN, Netherlands, October 2026 — Mair Therapeutics, a biotechnology company developing disease-modifying therapies for neurodegenerative disorders, announced that it has been awarded non-dilutive funding from Health~Holland to advance its first-in-class TMEM175-targeted therapeutic program for Parkinson's disease.
The grant will support research conducted in collaboration with Radboud University Medical Center (Radboud UMC) to further investigate restoration of lysosomal function, a key biological pathway implicated in Parkinson's disease progression.
"This award provides important external validation of both our scientific approach and our strategy of targeting lysosomal dysfunction in Parkinson's disease," said Dr. Vasily Kazey, Founder and CEO of Mair Therapeutics. "Growing genetic and biological evidence highlights TMEM175 as a promising therapeutic target, and this support enables us to accelerate development of our innovative therapeutic platform while strengthening the translational foundation for future clinical development."
TMEM175 is a lysosomal potassium channel genetically associated with Parkinson's disease risk and increasingly recognized as a key regulator of lysosomal homeostasis and cellular waste clearance. Impaired TMEM175 function contributes to defective lysosomal activity and the accumulation of toxic protein aggregates, including α-synuclein, a hallmark of Parkinson's disease pathology.
Mair Therapeutics is developing a portfolio of novel small-molecule TMEM175 agonists designed to restore lysosomal function and enhance intracellular clearance pathways. The company has identified a lead development candidate and is advancing the program through preclinical studies to evaluate its potential as a disease-modifying therapy for Parkinson's disease.
The collaboration with Radboud UMC will further characterize TMEM175 biology, evaluate translational biomarkers of target engagement in human cellular models, and generate additional preclinical evidence to support advancement of the company's lead program toward clinical development.
